Asklepios Klinik Altona

At Asklepios Klinik Altona in Hamburg, research in cardiovascular diseases focuses on acute ischemic stroke and high-risk transient ischemic attack. The studies are aimed at evaluating whether new approaches can better reduce the risk of another stroke and improve protection for people at high vascular risk.

• Assessing a new treatment strategy for stroke prevention after a recent ischemic event
• Studying how well therapy can lower the chance of recurrent cerebrovascular events

This line of research supports better long-term management of patients recovering from stroke or transient ischemic attack.

The site also conducts clinical trials in cancer, with a strong emphasis on hematology and blood-related tumors such as acute myeloid leukemia, multiple myeloma, and myelodysplastic syndrome. These studies are designed to improve treatment options and support patients with newly diagnosed or ongoing disease.

• Testing new treatment combinations for acute myeloid leukemia with a FLT3 mutation
• Evaluating longer-term access and safety for people with multiple myeloma benefiting from prior therapy
• Exploring improved control of myelodysplastic syndromes and related blood cancers

This research reflects an ongoing effort to make blood cancer care more effective and better tailored to disease biology.

A major part of the trial portfolio at this hospital involves metastatic colorectal cancer, including microsatellite instability-high and mismatch repair deficient disease, as well as other advanced colorectal tumors. The research is focused on improving treatment effectiveness and finding better ways to control tumors that no longer respond well to standard care.

• Comparing treatment approaches for MSI-H and dMMR colorectal cancer
• Studying new combinations to improve outcomes in advanced colorectal carcinoma
• Evaluating whether novel therapies can strengthen tumor control in difficult-to-treat disease

These studies aim to expand options for patients with metastatic colorectal cancer and other advanced neoplasms.

Research at Asklepios Klinik Altona also includes advanced non-clear cell renal cell carcinoma, with trials examining whether newer treatment combinations can improve disease control compared with established therapy. The focus is on patients with locally advanced or metastatic cancer who need more effective options.

• Testing a new combination approach for metastatic renal cell carcinoma
• Comparing treatment effectiveness against standard kidney cancer therapy

This work sits at the intersection of oncology and immunotherapy, with the goal of improving outcomes in hard-to-treat kidney tumors.